ticlopidine has been researched along with Peripheral Arterial Diseases in 68 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effect of ticagrelor compared to clopidogrel in patients with peripheral artery disease (PAD) and acute coronary syndromes (ACS)." | 9.20 | Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. ( Becker, RC; Emanuelsson, H; Hiatt, WR; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Patel, MR; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM, 2015) |
| " Patients with an episode of noncardioembolic ischemic stroke at least 8 days prior to randomization, who were aged <75 years or had a body weight >50 kg were randomized to 50 or 75 mg clopidogrel once daily for 52 weeks." | 9.16 | Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke. ( Minematsu, K; Tanahashi, N; Uchiyama, S, 2012) |
| "Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel." | 8.91 | Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015) |
| "To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)." | 7.85 | State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017) |
| "Clopidogrel or aspirin are indicated for patients with recent ischemic stroke (IS) or established peripheral artery disease (PAD)." | 7.81 | Clopidogrel versus aspirin in patients with recent ischemic stroke and established peripheral artery disease: an economic evaluation in a Chinese setting. ( Ben, H; Li, T; Liu, M; Wu, B; Xu, Z; Zhong, H, 2015) |
| "Although this database study indicated that cilostazol therapy is an effective alternative treatment for primary prevention of stroke in PAD, further confirmation is needed in large, prospective, and randomized trials." | 7.79 | Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan. ( Chu, CY; Hsu, PC; Lai, WT; Lee, WH; Lin, TH; Sheu, SH; Su, HM; Voon, WC, 2013) |
| "The novel P2Y12 antagonist ticagrelor inhibits adenosine diphosphate (ADP)-induced platelet aggregation more potently than clopidogrel and reduces the incidence of myocardial infarction and total death in patients with an acute coronary syndrome (ACS)." | 7.79 | Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. ( Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K, 2013) |
| "Patients with peripheral artery disease (PAD) following peripheral percutaneous transluminal angioplasty (PTA) with stent implantation are prone to stent thrombosis despite treatment with aspirin and clopidogrel." | 7.79 | Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease. ( Frołow, M; Mazur, P; Niżankowski, R; Sadowski, J; Undas, A, 2013) |
| "However, both trials revealed excess diplopia (double vision) usually reversible after vorapaxar." | 6.53 | Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation. ( Can, M; Fortmann, SD; Hanley, DF; Kim, MH; Lordkipanidze, M; Marciniak, TA; Rao, SV; Serebruany, VL; Tanguay, JF, 2016) |
| "The EUCLID trial investigated the effect of monotherapy with ticagrelor versus clopidogrel in 13,885 patients with peripheral artery disease (PAD); the primary endpoint was cardiovascular death, myocardial infarction, or ischaemic stroke." | 5.27 | Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial. ( Baumgartner, I; Berger, JS; Björck, M; Blomster, JI; Fowkes, FGR; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Norgren, L; Patel, MR; Rockhold, FW; Wojdyla, DM, 2018) |
| "The DAPT (Dual Antiplatelet Therapy) study randomized 11,648 patients free from ischemic and bleeding events 12 months after coronary stenting to continued thienopyridine plus aspirin therapy for an additional 18 months versus aspirin therapy alone." | 5.24 | Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. ( Apruzzese, PK; Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017) |
| " Ticagrelor, a potent, reversibly binding P2Y12 receptor antagonist, is beneficial in patients with acute coronary syndrome and prior myocardial infarction." | 5.22 | Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. ( Baumgartner, I; Berger, JS; Blomster, J; Fowkes, FG; Heizer, G; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Millegård, M; Norgren, L; Patel, MR; Reist, C, 2016) |
| "To determine the effect of ticagrelor compared to clopidogrel in patients with peripheral artery disease (PAD) and acute coronary syndromes (ACS)." | 5.20 | Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. ( Becker, RC; Emanuelsson, H; Hiatt, WR; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Patel, MR; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM, 2015) |
| " Patients with an episode of noncardioembolic ischemic stroke at least 8 days prior to randomization, who were aged <75 years or had a body weight >50 kg were randomized to 50 or 75 mg clopidogrel once daily for 52 weeks." | 5.16 | Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke. ( Minematsu, K; Tanahashi, N; Uchiyama, S, 2012) |
| "Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel." | 4.91 | Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015) |
| "The use of aspirin is considered the "gold standard" for the decrease of major adverse cardiovascular events in patients with atherosclerosis, including peripheral arterial disease (PAD), whereas a dual-antiplatelet regimen with aspirin and clopidogrel is usually indicated for such patients after angioplasty and stent deployment." | 4.90 | High on-treatment platelet reactivity in peripheral endovascular procedures. ( Hatzidakis, A; Kassimis, G; Krokidis, M; Spiliopoulos, S, 2014) |
| "This review focuses on the use of clopidogrel and the phenomenon of HCPR in PAD patients treated for intermittent claudication or critical limb ischaemia (CLI)." | 4.90 | Efficacy of clopidogrel treatment and platelet responsiveness in peripheral arterial procedures. ( Diamantopoulos, A; Katsanos, K; Pastromas, G; Spiliopoulos, S, 2014) |
| "To assess the clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole (MRD) alone or with aspirin (ASA) compared with ASA (and each other where appropriate) in the prevention of occlusive vascular events in patients with a history of MI, ischaemic stroke/TIA or established peripheral arterial disease." | 4.87 | Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. ( Bagust, A; Blundell, M; Boland, A; Dickson, R; Dundar, Y; Fisher, M; Greenhalgh, J; Martin Saborido, C; Oyee, J; Proudlove, C, 2011) |
| "To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)." | 3.85 | State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017) |
| "Restenosis and stent thrombosis after endovascular intervention in patients with peripheral arterial disease (PAD) can potentially be tackled by more intensive antiplatelet therapy, such as dual antiplatelet therapy (DAPT) consisting of aspirin and P2Y12 inhibitor." | 3.83 | High On-Treatment Platelet Reactivity in Peripheral Arterial Disease: A Pilot Study to Find the Optimal Test and Cut Off Values. ( Asselbergs, FW; de Borst, GJ; den Ruijter, HM; Leunissen, TC; Moll, FL; Peeters Weem, SM; Urbanus, RT, 2016) |
| "Clopidogrel or aspirin are indicated for patients with recent ischemic stroke (IS) or established peripheral artery disease (PAD)." | 3.81 | Clopidogrel versus aspirin in patients with recent ischemic stroke and established peripheral artery disease: an economic evaluation in a Chinese setting. ( Ben, H; Li, T; Liu, M; Wu, B; Xu, Z; Zhong, H, 2015) |
| "Current guidelines recommend antithrombotic therapy with either aspirin or clopidogrel for all patients with peripheral arterial disease (PAD)." | 3.81 | Adverse cardiovascular outcomes in relation to suboptimal antithrombotic therapy use in patients undergoing peripheral artery disease angioplasty: lost opportunities? ( Allon, IR; Apostolakis, S; Bodansky, DM; Lip, GY, 2015) |
| "This study was conducted to determine whether there is additive benefit of dual-antiplatelet therapy (DAPT) with aspirin (acetylsalicylic acid [ASA]) and clopidogrel compared with ASA monotherapy among patients with symptomatic peripheral arterial disease." | 3.81 | Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease. ( Amsterdam, EA; Anderson, DR; Armstrong, EJ; Bang, H; Freischlag, JA; Laird, JR; Singh, GD; Yeo, KK, 2015) |
| " Patients with critical limb ischemia following stent thrombosis were included if dual antiplatelet therapy consisting of 100 mg aspirin and 75 mg clopidogrel per day had been administered over three months prior to enrollment." | 3.80 | Response to dual antiplatelet therapy in patients with peripheral artery occlusive disease suffering from critical limb ischemia. ( Baecker, C; Baro, D; Meybohm, P; Mutlak, H; Schmitz-Rixen, T; Wand, S; Weber, CF; Zacharowski, K, 2014) |
| "Although this database study indicated that cilostazol therapy is an effective alternative treatment for primary prevention of stroke in PAD, further confirmation is needed in large, prospective, and randomized trials." | 3.79 | Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan. ( Chu, CY; Hsu, PC; Lai, WT; Lee, WH; Lin, TH; Sheu, SH; Su, HM; Voon, WC, 2013) |
| "Patients with peripheral artery disease (PAD) following peripheral percutaneous transluminal angioplasty (PTA) with stent implantation are prone to stent thrombosis despite treatment with aspirin and clopidogrel." | 3.79 | Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease. ( Frołow, M; Mazur, P; Niżankowski, R; Sadowski, J; Undas, A, 2013) |
| "The novel P2Y12 antagonist ticagrelor inhibits adenosine diphosphate (ADP)-induced platelet aggregation more potently than clopidogrel and reduces the incidence of myocardial infarction and total death in patients with an acute coronary syndrome (ACS)." | 3.79 | Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. ( Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K, 2013) |
| "As of March 2009, 1222 patients were using clopidogrel: 595 had coronary artery disease, 329 cerebrovascular disease, and 298 had peripheral artery disease." | 3.77 | Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de Riesgo y ENfermedad Arterial (FRENA) registry. ( Escudero, D; Monreal, M; Muñoz-Torrero, JF; Pascual, MT; Sanclemente, C; Suárez, C; Trujillo-Santos, J; Zamorano, J, 2011) |
| "Peripheral artery disease is considered to be a manifestation of systemic atherosclerosis with associated adverse cardiovascular and limb events." | 2.84 | Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. ( Baumgartner, I; Berger, JS; Blomster, J; Fowkes, FG; Heizer, G; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Millegård, M; Norgren, L; Patel, MR; Reist, C, 2017) |
| "Sarpogrelate is expected to reduce restenosis by protecting blood vessels from oxidative stress and vascular endothelial dysfunction as well as by acting as an antiplatelet agent after endovascular treatment (EVT)." | 2.84 | SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial. ( Ahn, S; Cho, MJ; Cho, S; Ha, J; Kim, SY; Lee, J; Min, SI; Min, SK, 2017) |
| "Cilostazol has been reported to reduce intimal hyperplasia and subsequent repeat revascularization." | 2.79 | Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial. ( Bae, JH; Baek, JY; Bong, JM; Cho, JH; Cho, YH; Choi, CU; Choi, HJ; Choi, SH; Choi, WG; Chung, WY; Her, SH; Kang, WY; Kim, EJ; Kim, JH; Kim, KC; Kim, MW; Kim, SM; Kim, WH; Kim, YH; Kim, YJ; Lee, SJ; Oh, DJ; Park, MW; Park, SH; Rha, SW; Seo, JB; Soh, JW; Suh, J, 2014) |
| "Patients with peripheral artery disease are at high-risk for cardiovascular events." | 2.58 | [Anti-Thrombotic Treatment of Patients with Peripheral Artery Disease (PAD)]. ( Espinola-Klein, C, 2018) |
| "However, both trials revealed excess diplopia (double vision) usually reversible after vorapaxar." | 2.53 | Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation. ( Can, M; Fortmann, SD; Hanley, DF; Kim, MH; Lordkipanidze, M; Marciniak, TA; Rao, SV; Serebruany, VL; Tanguay, JF, 2016) |
| "In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of peripheral artery disease (PAD), producing intermittent claudication (IC), ischemic necrosis, and, potentially, loss of the limb." | 2.50 | Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. ( Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E, 2014) |
| "Atorvastatin 80 mg was found to be independent predictor of survival, and major amputation was found to be independent predictor of mortality." | 1.39 | Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry). ( Buszman, PE; Buszman, PP; Kiesz, RS; Konkolewska, MD; Martin, JL; Radvany, MG; Szymanski, R; Wiernek, BK; Wiernek, SL, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 63 (92.65) | 24.3611 |
| 2020's | 5 (7.35) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Y | 1 |
| Chou, JW | 1 |
| Huang, WT | 1 |
| Derry, K | 1 |
| Humber, D | 1 |
| Kim, Y | 1 |
| Weissler, EH | 1 |
| Pack, N | 1 |
| Latz, CA | 1 |
| Suarez Ferreira, SP | 1 |
| Hall, RP | 1 |
| Majumdar, M | 1 |
| Goudot, G | 1 |
| Jessula, S | 1 |
| Bellomo, T | 1 |
| Lee, I | 1 |
| Kukreja, N | 1 |
| Parmar, G | 1 |
| Boada, AE | 1 |
| Dua, A | 1 |
| Cha, JJ | 1 |
| Cho, JY | 1 |
| Lim, S | 1 |
| Kim, JH | 2 |
| Joo, HJ | 1 |
| Park, JH | 1 |
| Hong, SJ | 1 |
| Lim, DS | 1 |
| Kook, H | 1 |
| Lee, SH | 1 |
| Ko, YG | 1 |
| Min, PK | 1 |
| Lee, JH | 1 |
| Yoon, CH | 1 |
| Chae, IH | 1 |
| Lee, SW | 1 |
| Lee, SR | 1 |
| Choi, SH | 2 |
| Koh, YS | 1 |
| Yu, CW | 1 |
| Chiarito, M | 1 |
| Sanz-Sánchez, J | 1 |
| Cannata, F | 1 |
| Cao, D | 1 |
| Sturla, M | 1 |
| Panico, C | 1 |
| Godino, C | 1 |
| Regazzoli, D | 1 |
| Reimers, B | 1 |
| De Caterina, R | 1 |
| Condorelli, G | 1 |
| Ferrante, G | 1 |
| Stefanini, GG | 1 |
| Ahn, J-H | 1 |
| Gurbel, PA | 1 |
| Jeong, Y-H | 1 |
| Patel, MR | 7 |
| Fowkes, FG | 4 |
| Hiatt, WR | 6 |
| Uzoigwe, FA | 1 |
| Secemsky, EA | 2 |
| Yeh, RW | 2 |
| Kereiakes, DJ | 1 |
| Cutlip, DE | 1 |
| Steg, PG | 2 |
| Massaro, JM | 1 |
| Apruzzese, PK | 1 |
| Mauri, L | 2 |
| Moris, D | 1 |
| Patelis, N | 1 |
| Kakkos, S | 1 |
| Lozano, I | 1 |
| Rondan, J | 1 |
| Vegas, JM | 1 |
| Segovia, E | 1 |
| Guirgis, M | 1 |
| Thompson, P | 1 |
| Jansen, S | 1 |
| Ahn, S | 1 |
| Lee, J | 1 |
| Min, SK | 1 |
| Ha, J | 1 |
| Min, SI | 1 |
| Kim, SY | 1 |
| Cho, MJ | 1 |
| Cho, S | 1 |
| Norgren, L | 4 |
| Wojdyla, DM | 2 |
| Fowkes, FGR | 2 |
| Baumgartner, I | 5 |
| Mahaffey, KW | 5 |
| Berger, JS | 4 |
| Jones, WS | 5 |
| Katona, BG | 4 |
| Held, P | 4 |
| Blomster, JI | 1 |
| Rockhold, FW | 1 |
| Björck, M | 1 |
| Cea-Soriano, L | 1 |
| Johansson, S | 1 |
| Allum, AM | 1 |
| García Rodriguez, LA | 1 |
| Hernandez-Suarez, DF | 1 |
| Núñez-Medina, H | 1 |
| Scott, SA | 1 |
| Lopez-Candales, A | 1 |
| Wiley, JM | 1 |
| Garcia, MJ | 1 |
| Melin, K | 1 |
| Nieves-Borrero, K | 1 |
| Rodriguez-Ruiz, C | 1 |
| Marshall, L | 1 |
| Duconge, J | 1 |
| Henni, S | 1 |
| Ouedraogo, N | 1 |
| Abraham, P | 1 |
| Shatila, W | 1 |
| Krajcer, Z | 1 |
| Espinola-Klein, C | 1 |
| Xiang, Y | 1 |
| Wang, J | 1 |
| Zhao, J | 1 |
| Huang, B | 1 |
| Pastromas, G | 2 |
| Spiliopoulos, S | 4 |
| Katsanos, K | 2 |
| Diamantopoulos, A | 2 |
| Kitrou, P | 1 |
| Karnabatidis, D | 1 |
| Siablis, D | 1 |
| Lee, WH | 1 |
| Chu, CY | 1 |
| Hsu, PC | 1 |
| Su, HM | 1 |
| Lin, TH | 1 |
| Voon, WC | 1 |
| Lai, WT | 1 |
| Sheu, SH | 1 |
| Torngren, K | 1 |
| Ohman, J | 1 |
| Salmi, H | 1 |
| Larsson, J | 1 |
| Erlinge, D | 1 |
| Kassimis, G | 1 |
| Hatzidakis, A | 1 |
| Krokidis, M | 1 |
| Strobl, FF | 1 |
| Brechtel, K | 1 |
| Schmehl, J | 1 |
| Zeller, T | 1 |
| Reiser, MF | 2 |
| Claussen, CD | 1 |
| Tepe, G | 1 |
| Gremmel, T | 2 |
| Koppensteiner, R | 2 |
| Ay, C | 1 |
| Panzer, S | 2 |
| Xhelili, E | 1 |
| Steiner, S | 1 |
| Kopp, CW | 1 |
| Kuznetsov, MR | 1 |
| Sergeeva, NA | 1 |
| Koshkin, VM | 1 |
| Boldin, BV | 1 |
| Rodionov, SV | 1 |
| Virganskiĭ, AO | 1 |
| Kosykh, IV | 1 |
| Lisenkov, OP | 1 |
| Kuznetsova, VF | 1 |
| George, JC | 1 |
| Rosen, ES | 1 |
| Nachtigall, J | 1 |
| VanHise, A | 1 |
| Kovach, R | 1 |
| Becker, RC | 1 |
| Emanuelsson, H | 1 |
| Horrow, J | 1 |
| Husted, S | 1 |
| Storey, RF | 1 |
| Wallentin, L | 1 |
| James, SK | 1 |
| Bodansky, DM | 1 |
| Allon, IR | 1 |
| Apostolakis, S | 1 |
| Lip, GY | 1 |
| Di Minno, G | 1 |
| Spadarella, G | 1 |
| Cafaro, G | 1 |
| Petitto, M | 1 |
| Lupoli, R | 1 |
| Di Minno, A | 1 |
| de Gaetano, G | 1 |
| Tremoli, E | 1 |
| Park, SH | 1 |
| Rha, SW | 1 |
| Choi, CU | 1 |
| Kim, EJ | 1 |
| Oh, DJ | 1 |
| Cho, YH | 1 |
| Choi, WG | 1 |
| Lee, SJ | 1 |
| Kim, YH | 1 |
| Kim, WH | 1 |
| Kim, KC | 1 |
| Cho, JH | 1 |
| Kim, SM | 1 |
| Bae, JH | 1 |
| Bong, JM | 1 |
| Kang, WY | 1 |
| Baek, JY | 1 |
| Seo, JB | 1 |
| Chung, WY | 1 |
| Park, MW | 1 |
| Her, SH | 1 |
| Suh, J | 1 |
| Kim, MW | 1 |
| Kim, YJ | 1 |
| Choi, HJ | 1 |
| Soh, JW | 1 |
| Schmit, K | 1 |
| Dolor, RJ | 1 |
| Vemulapalli, S | 1 |
| Hasselblad, V | 1 |
| Subherwal, S | 1 |
| Heidenfelder, B | 1 |
| Wand, S | 1 |
| Baro, D | 1 |
| Baecker, C | 1 |
| Meybohm, P | 1 |
| Schmitz-Rixen, T | 1 |
| Zacharowski, K | 1 |
| Mutlak, H | 1 |
| Weber, CF | 1 |
| Treitl, KM | 1 |
| König, C | 1 |
| Treitl, M | 1 |
| Tangelder, MJ | 1 |
| Nwachuku, CE | 1 |
| Jaff, M | 1 |
| Duggal, A | 1 |
| Adams, G | 1 |
| Ansel, G | 1 |
| Grosso, M | 1 |
| Mercuri, M | 1 |
| Shi, M | 1 |
| Minar, E | 1 |
| Moll, FL | 2 |
| Armstrong, EJ | 1 |
| Anderson, DR | 1 |
| Yeo, KK | 1 |
| Singh, GD | 1 |
| Bang, H | 1 |
| Amsterdam, EA | 1 |
| Freischlag, JA | 1 |
| Laird, JR | 1 |
| Li, T | 1 |
| Liu, M | 1 |
| Ben, H | 1 |
| Xu, Z | 1 |
| Zhong, H | 1 |
| Wu, B | 1 |
| Arif, SA | 1 |
| D'Souza, J | 1 |
| Gil, M | 1 |
| Gim, S | 1 |
| Reed Chase, M | 1 |
| Friedman, HS | 1 |
| Navaratnam, P | 1 |
| Heithoff, K | 1 |
| Simpson, RJ | 1 |
| Serebruany, VL | 1 |
| Fortmann, SD | 1 |
| Rao, SV | 1 |
| Tanguay, JF | 1 |
| Lordkipanidze, M | 1 |
| Hanley, DF | 1 |
| Can, M | 1 |
| Kim, MH | 1 |
| Marciniak, TA | 1 |
| Bernlochner, I | 1 |
| Jaitner, J | 1 |
| Fries, V | 1 |
| Dommasch, M | 1 |
| Mayer, K | 1 |
| Ott, I | 1 |
| Langwieser, N | 1 |
| Fusaro, M | 1 |
| Laugwitz, KL | 1 |
| Kastrati, A | 1 |
| Ibrahim, T | 1 |
| Fromonot, J | 1 |
| Dignat-Georges, F | 1 |
| Rossi, P | 1 |
| Mottola, G | 1 |
| Kipson, N | 1 |
| Ruf, J | 1 |
| Bonello, L | 1 |
| Guieu, R | 1 |
| Paganelli, F | 1 |
| Blomster, J | 3 |
| Millegård, M | 3 |
| Heizer, G | 3 |
| Reist, C | 3 |
| Leunissen, TC | 1 |
| Peeters Weem, SM | 1 |
| Urbanus, RT | 1 |
| den Ruijter, HM | 1 |
| Asselbergs, FW | 1 |
| de Borst, GJ | 1 |
| Díaz-Villamarín, X | 1 |
| Dávila-Fajardo, CL | 1 |
| Martínez-González, LJ | 1 |
| Carmona-Sáez, P | 1 |
| Sánchez-Ramos, J | 1 |
| Álvarez Cubero, MJ | 1 |
| Salmerón-Febres, LM | 1 |
| Cabeza Barrera, J | 1 |
| Fernández-Quesada, F | 1 |
| Conte, MS | 2 |
| White, CJ | 1 |
| Fernández-Ruiz, I | 1 |
| Thott, O | 1 |
| Granath, F | 1 |
| Malmstedt, J | 1 |
| Wahlgren, CM | 1 |
| Jones, DW | 1 |
| Schermerhorn, ML | 1 |
| Brooke, BS | 1 |
| Conrad, MF | 1 |
| Goodney, PP | 2 |
| Wyers, MC | 1 |
| Stone, DH | 2 |
| Du, M | 1 |
| Chase, M | 1 |
| Oguz, M | 1 |
| Davies, G | 1 |
| Gupta, R | 1 |
| Kirtane, AJ | 1 |
| Ozan, MO | 1 |
| Witzenbichler, B | 1 |
| Rinaldi, MJ | 1 |
| Metzger, DC | 1 |
| Weisz, G | 1 |
| Stuckey, TD | 1 |
| Brodie, BR | 1 |
| Mehran, R | 1 |
| Ben-Yehuda, O | 1 |
| Stone, GW | 1 |
| Muñoz-Torrero, JF | 1 |
| Escudero, D | 1 |
| Suárez, C | 1 |
| Sanclemente, C | 1 |
| Pascual, MT | 1 |
| Zamorano, J | 1 |
| Trujillo-Santos, J | 1 |
| Monreal, M | 1 |
| Schanzer, A | 1 |
| Nolan, BW | 1 |
| Adams, JE | 1 |
| Powell, RJ | 1 |
| Walsh, DB | 1 |
| Cronenwett, JL | 1 |
| Yan, BP | 1 |
| Ajani, AE | 1 |
| Clark, DJ | 1 |
| Duffy, SJ | 1 |
| Andrianopoulos, N | 1 |
| Brennan, AL | 1 |
| Loane, P | 1 |
| Reid, CM | 1 |
| Greenhalgh, J | 1 |
| Bagust, A | 1 |
| Boland, A | 1 |
| Martin Saborido, C | 1 |
| Oyee, J | 1 |
| Blundell, M | 1 |
| Dundar, Y | 1 |
| Dickson, R | 1 |
| Proudlove, C | 1 |
| Fisher, M | 1 |
| Mazur, P | 1 |
| Frołow, M | 1 |
| Niżankowski, R | 1 |
| Sadowski, J | 1 |
| Undas, A | 1 |
| Meltzer, AJ | 1 |
| Da Silva, P | 1 |
| Schneider, DB | 1 |
| Shrikhande, GV | 1 |
| Uchiyama, S | 1 |
| Tanahashi, N | 1 |
| Minematsu, K | 1 |
| Bötticher, G | 1 |
| Gäbel, G | 1 |
| Weiss, N | 1 |
| Saeger, HD | 1 |
| Bergert, H | 1 |
| Kiesz, RS | 1 |
| Wiernek, SL | 1 |
| Wiernek, BK | 1 |
| Radvany, MG | 1 |
| Buszman, PP | 1 |
| Szymanski, R | 1 |
| Konkolewska, MD | 1 |
| Martin, JL | 1 |
| Buszman, PE | 1 |
| Hanna, EB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial[NCT02959606] | Phase 4 | 272 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease[NCT01732822] | Phase 3 | 13,885 participants (Actual) | Interventional | 2012-12-04 | Completed | ||
| Influence of Platelet Reactivity in Peripheral Arterial Disease Patients Undergoing Percutaneous Angioplasty on Mid-term Outcomes[NCT04165629] | 450 participants (Anticipated) | Observational | 2020-01-01 | Recruiting | |||
| Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function and Other Circulating Biomarkers in Humans[NCT02587260] | Phase 4 | 54 participants (Actual) | Interventional | 2015-12-17 | Completed | ||
| Follow-up Management of Peripheral Arterial Intervention With Clopidogrel MIRROR-Study[NCT00163267] | Phase 2/Phase 3 | 80 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872] | Phase 3 | 18,624 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Efficacy of Self-Expanding Nitinol S.M.A.R.T-CONTROL Stent Versus Complete SE Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP Trial)[NCT01570803] | 0 participants (Actual) | Interventional | 2013-01-31 | Withdrawn (stopped due to Study could not be initiated due to lack of research funding from the sponsors.) | |||
| A Randomized, Open-Label, Parallel-Group, Multi-Center Study Of Adding Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention[NCT01802775] | Phase 2 | 203 participants (Actual) | Interventional | 2013-02-06 | Completed | ||
| Alignment of Treatment Preferences and Repair Type for Veterans With AAA[NCT03115346] | 238 participants (Anticipated) | Interventional | 2017-04-15 | Active, not recruiting | |||
| Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794] | 8,575 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization[NCT03953547] | 88 participants (Actual) | Observational | 2018-01-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with ALI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 117 |
| Clopidogrel 75 mg od | 115 |
Participants with all-cause death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 628 |
| Clopidogrel 75 mg od | 635 |
Participants with any amputation caused by peripheral arterial disease (PAD). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 179 |
| Clopidogrel 75 mg od | 208 |
Participants with any revascularization. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1211 |
| Clopidogrel 75 mg od | 1250 |
Participants with CV death, myocardial infarction (MI) or ischemic stroke. If no event, censoring occurs at the minimum of (primary analysis censoring date (PACD), last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg bd | 751 |
| Clopidogrel 75 mg od | 740 |
Participants with CV death, MI or all-cause stroke. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 766 |
| Clopidogrel 75 mg od | 759 |
Participants with CV death, MI, ischemic stroke or acute limb ischemia (ALI). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 839 |
| Clopidogrel 75 mg od | 833 |
Participants with CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 363 |
| Clopidogrel 75 mg od | 343 |
Participants with hospitalization associated with CV death, hospitalization due to MI, ischemic stroke, lower extremity revascularization, major amputation due to PAD, transient ischemic attack (TIA), coronary revascularization or unstable angina. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1312 |
| Clopidogrel 75 mg od | 1314 |
Participants with lower extremity revascularization (LER). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 846 |
| Clopidogrel 75 mg od | 892 |
Participants with major amputation caused by PAD. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 100 |
| Clopidogrel 75 mg od | 116 |
Participants with MI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 349 |
| Clopidogrel 75 mg od | 334 |
Participants with all-cause death, MI, ischemic stroke, ALI, major amputation, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1119 |
| Clopidogrel 75 mg od | 1140 |
Participants with all-cause death, MI, ischemic stroke, ALI, major amputation or Thrombolysis in Myocardial Infarction (TIMI) major bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1183 |
| Clopidogrel 75 mg od | 1199 |
Participants with all-cause death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 983 |
| Clopidogrel 75 mg od | 992 |
Participants with CV death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 789 |
| Clopidogrel 75 mg od | 786 |
Participants with non-CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, CV death) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 250 |
| Clopidogrel 75 mg od | 272 |
Participants with PLATO major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 206 |
| Clopidogrel 75 mg od | 188 |
Participants with a permanent discontinuation of study drug due to any bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 168 |
| Clopidogrel 75 mg od | 112 |
Participants with TIMI major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 113 |
| Clopidogrel 75 mg od | 109 |
Participants with TIMI major or minor bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 193 |
| Clopidogrel 75 mg od | 175 |
"Change in ankle brachial index (ABI) / toe brachial index (TBI).~Ankle brachial index (ABI) is the ratio of blood pressures from the ankle and arm and is used for diagnosing peripheral arterial occlusive disease (PAOD):~Normal: 1 to 1.29 Borderline: 0.91 to 0.99 Mild PAOD: 0.71 to 0.90 Medium severe PAOD: 0.41 to 0.7 Severe PAOD: <0.4~Toe brachial index (TBI) is the ratio between the toe pressure and the higher brachial pressure, used for diagnosing PAOD when the ABI cannot be used:~Normal: >0.7 Mild: 0.5-0.7 Moderate: 0.35-0.5 Moderate-Severe: <0.35 and toe pressure 40 mmHg Severe: <0.35 and toe pressure < 30 mmHg" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Change in ABI/TBI (Mean) | |||
|---|---|---|---|---|
| ABI - 6 months N = 6184(Tica), 6319(Clopi) | ABI - End of treatment N = 4951(Tica), 5073(Clopi) | TBI - 6 months N = 55(Tica), 48(Clopi) | TBI - End of treatment N = 36(Tica), 21(Clopi) | |
| Clopidogrel 75 mg od | 0.011 | 0.016 | 0.036 | -0.065 |
| Ticagrelor 90 mg bd | 0.016 | 0.022 | 0.050 | 0.059 |
"Progression of the clinical/symptomatic status of the limb by changes in Fontaine stage.~Stage I - Asymptomatic Stage IIa - Intermittent claudication after more than 200 meters of pain free walking Stage IIb - Intermittent claudication after less than 200 meters of walking Stage III - Rest pain Stage IV - Ischemic ulcers or gangrene" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) | |||||
|---|---|---|---|---|---|---|
| Stage I - End of treatment | Stage IIa - End of treatment | Stage IIb - End of treatment | Stage III - End of treatment | Stage IV - End of treatment | Missing - End of treatment | |
| Clopidogrel - Stage I | 743 | 230 | 56 | 9 | 4 | 250 |
| Clopidogrel - Stage IIa | 723 | 1956 | 311 | 15 | 7 | 724 |
| Clopidogrel - Stage IIb | 198 | 557 | 450 | 23 | 10 | 370 |
| Clopidogrel - Stage III | 33 | 33 | 38 | 23 | 5 | 60 |
| Clopidogrel - Stage IV | 19 | 21 | 15 | 12 | 13 | 45 |
| Ticagrelor - Stage I | 775 | 227 | 45 | 7 | 7 | 248 |
| Ticagrelor - Stage IIa | 683 | 1948 | 269 | 24 | 7 | 743 |
| Ticagrelor - Stage IIb | 171 | 560 | 469 | 12 | 5 | 403 |
| Ticagrelor - Stage III | 15 | 41 | 39 | 31 | 1 | 59 |
| Ticagrelor - Stage IV | 26 | 28 | 19 | 7 | 13 | 47 |
"Progression of the clinical/symptomatic status of the limb by changes in Rutherford classification.~Category 0 - Asymptomatic Category 1 - Mild claudication Category 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.~Category 3 - Severe claudication Category 4 - Rest pain Category 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Category 6 - Severe ischemic ulcers or frank gangrene" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Category 0 - End of treatment | Category 1/2 - End of treatment | Category 3 - End of treatment | Category 4 - End of treatment | Category 5 - End of treatment | Category 6 - End of treatment | Missing - End of treatment | |
| Clopidogrel - Cat 0 | 743 | 230 | 56 | 9 | 2 | 2 | 250 |
| Clopidogrel - Cat 1/2 | 723 | 1956 | 311 | 15 | 6 | 1 | 724 |
| Clopidogrel - Cat 3 | 198 | 557 | 450 | 23 | 6 | 4 | 370 |
| Clopidogrel - Cat 4 | 33 | 33 | 38 | 23 | 4 | 1 | 60 |
| Clopidogrel - Cat 5 | 13 | 18 | 12 | 11 | 12 | 0 | 34 |
| Clopidogrel - Cat 6 | 6 | 3 | 3 | 1 | 1 | 0 | 11 |
| Ticagrelor - Cat 0 | 775 | 227 | 45 | 7 | 5 | 2 | 248 |
| Ticagrelor - Cat 3 | 171 | 560 | 469 | 12 | 3 | 2 | 403 |
| Ticagrelor - Cat 4 | 15 | 41 | 39 | 31 | 1 | 0 | 59 |
| Ticagrelor - Cat 5 | 23 | 23 | 13 | 4 | 11 | 0 | 33 |
| Ticagrelor - Cat 6 | 3 | 5 | 6 | 3 | 0 | 2 | 14 |
| Ticagrelor - Stage II | 683 | 1948 | 269 | 24 | 4 | 3 | 743 |
Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 901 |
| CLOPIDOGREL | 1065 |
Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1290 |
| CLOPIDOGREL | 1456 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 569 |
| CLOPIDOGREL | 668 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 864 |
| CLOPIDOGREL | 1014 |
Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 961 |
| CLOPIDOGREL | 929 |
Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 619 |
| CLOPIDOGREL | 654 |
Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 329 |
| CLOPIDOGREL | 341 |
Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 399 |
| CLOPIDOGREL | 506 |
Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 353 |
| CLOPIDOGREL | 442 |
Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1339 |
| CLOPIDOGREL | 1215 |
Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 504 |
| CLOPIDOGREL | 593 |
Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 362 |
| CLOPIDOGREL | 306 |
Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 235 |
| CLOPIDOGREL | 180 |
Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 125 |
| CLOPIDOGREL | 106 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 21 |
| CLOPIDOGREL | 16 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 84 |
| CLOPIDOGREL | 51 |
Number of Adjudicated Major Adverse Cardiovascular Events (MACE) which is a composite of non-fatal myocardial infarction (MI), non-fatal stroke and cardiovascular death (NCT01802775)
Timeframe: within 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 1 |
| Edoxaban | 3 |
Number of participants with amputations within 6 months (NCT01802775)
Timeframe: within 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 3 |
| Edoxaban | 1 |
Percentage of participants with re-stenosis/re-occlusion during treatment within 6 months - only the first occurrence of re-stenosis / re-occlusion was counted for each participant (NCT01802775)
Timeframe: within 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Clopidogrel | 34.7 |
| Edoxaban | 30.9 |
"Number of participants with serious adverse events (SAEs) within 6 months~Note: Based on changes to the database structure, clinically significant changes in physical or laboratory parameters are recorded as adverse events (AEs). Details of non-serious adverse events are reported at the 5% reporting threshold in the AE module, as is all-cause mortality." (NCT01802775)
Timeframe: within 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 30 |
| Edoxaban | 31 |
Percentage of participants with clinically relevant bleeding, defined as major bleeding or clinical relevant non-major bleeding, in the on-treatment period based on International Society of Thrombosis and Haemostasis (ISTH) (NCT01802775)
Timeframe: at 3 months
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Including Access Site Bleeding (IASB) | Excluding Access Site Bleed (EASB) | |
| Clopidogrel | 8 | 6 |
| Edoxaban | 11 | 6 |
The percentage of participants with major, clinically relevant non-major, and minor bleeding occurring during treatment, within 3 months (NCT01802775)
Timeframe: within 3 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| IASB : Major Bleeding | IASB: CRNM Bleeding | IASB: Minor Bleeding | EASB : Major Bleeding | EASB : CRNM Bleeding | EASB : Minor Bleeding | |
| Clopidogrel | 5 | 4 | 20.8 | 4 | 3 | 17.8 |
| Edoxaban | 1 | 10 | 20 | 1 | 5 | 19 |
15 reviews available for ticlopidine and Peripheral Arterial Diseases
| Article | Year |
|---|---|
Platelet reactivity testing in peripheral artery disease.
Topics: Blood Platelets; Clopidogrel; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; | 2022 |
A Systematic Review of Clopidogrel Resistance in Vascular Surgery: Current Perspectives and Future Directions.
Topics: Cerebrovascular Disorders; Clopidogrel; Humans; Peripheral Arterial Disease; Platelet Aggregation In | 2023 |
Monotherapy with a P2Y
Topics: Aged; Aspirin; Atherosclerosis; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Female; He | 2020 |
Review of aspirin and clopidogrel resistance in peripheral arterial disease.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Genotype; Humans; Peripheral Arteri | 2017 |
[Anti-Thrombotic Treatment of Patients with Peripheral Artery Disease (PAD)].
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Dr | 2018 |
High on-treatment platelet reactivity in peripheral endovascular procedures.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Clopidogrel; Endovascular Procedures; Humans; Peripheral | 2014 |
Antiplatelet therapy in critical limb ischemia: update on clopidogrel and cilostazol.
Topics: Cilostazol; Clopidogrel; Combined Modality Therapy; Critical Illness; Drug Therapy, Combination; End | 2014 |
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Int | 2014 |
Efficacy of clopidogrel treatment and platelet responsiveness in peripheral arterial procedures.
Topics: Blood Platelets; Clopidogrel; Endovascular Procedures; Humans; Intermittent Claudication; Peripheral | 2014 |
Comparative effectiveness review of antiplatelet agents in peripheral artery disease.
Topics: Aspirin; Clopidogrel; Comparative Effectiveness Research; Drug Therapy, Combination; Humans; Patient | 2014 |
Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Half-Life; Hemorrhage; Humans; L | 2015 |
Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation.
Topics: Animals; Aspirin; Clopidogrel; Diplopia; Drug Approval; Eye; Humans; Lactones; Peripheral Arterial D | 2016 |
Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty.
Topics: Aged; Angioplasty; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Cyto | 2016 |
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Delayed-Ac | 2011 |
[Antithrombotic therapy after peripheral vascular treatment: what is evidence-based?].
Topics: Aortic Diseases; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Dose-Response Relations | 2012 |
13 trials available for ticlopidine and Peripheral Arterial Diseases
| Article | Year |
|---|---|
Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug | 2017 |
SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial.
Topics: Amputation, Surgical; Aspirin; Clinical Protocols; Clopidogrel; Computed Tomography Angiography; Con | 2017 |
Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial.
Topics: Adenosine; Aged; Clopidogrel; Female; Hospitalization; Humans; Hypertension; Incidence; Ischemia; Ka | 2018 |
Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy.
Topics: Aged; Aryldialkylphosphatase; ATP Binding Cassette Transporter, Subfamily B; Blood Platelets; Cilost | 2018 |
Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Aspirin; Clopidogrel; Double-Blind Method; Drug Thera | 2013 |
Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Huma | 2015 |
Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial.
Topics: Alloys; Angioplasty, Balloon; Aspirin; Cilostazol; Clinical Protocols; Clopidogrel; Drug Therapy, Co | 2014 |
A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
Topics: Aged; Angioplasty; Aspirin; Clopidogrel; Drug Therapy, Combination; Europe; Factor Xa Inhibitors; Fe | 2015 |
Ticagrelor Improves Peripheral Arterial Function in Acute Coronary Syndrome Patients: Relationship With Adenosine Plasma Level.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Arteries; Aspirin; Biomarkers; Clopidogrel; Dose-Response | 2016 |
Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial.
Topics: Adenosine; Aged; Ankle Brachial Index; Clopidogrel; Disease Progression; Female; Humans; Male; Middl | 2016 |
Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease.
Topics: Adenosine; Aged; Clopidogrel; Female; Humans; Lower Extremity; Male; Peripheral Arterial Disease; Pu | 2017 |
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease.
Topics: Adenosine; Aged; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Huma | 2017 |
Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke.
Topics: Age Factors; Aged; Asian People; Body Weight; Clopidogrel; Dose-Response Relationship, Drug; Double- | 2012 |
40 other studies available for ticlopidine and Peripheral Arterial Diseases
| Article | Year |
|---|---|
Atorvastatin Effect on Clopidogrel Efficacy in Patients with Peripheral Artery Disease.
Topics: Anticoagulants; Aspirin; Atorvastatin; Clopidogrel; Humans; Hydroxymethylglutaryl-CoA Reductase Inhi | 2023 |
Effect of Cilostazol on Patients With Diabetes Who Underwent Endovascular Treatment for Peripheral Artery Disease.
Topics: Cilostazol; Diabetes Mellitus; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; | 2023 |
Ticagrelor versus Clopidogrel in Peripheral Artery Disease.
Topics: Adenosine; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Ticlopidine | 2017 |
Ticagrelor versus Clopidogrel in Peripheral Artery Disease.
Topics: Adenosine; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Ticlopidine | 2017 |
Ticagrelor versus Clopidogrel in Peripheral Artery Disease.
Topics: Adenosine; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Ticlopidine | 2017 |
Letter by Moris et al Regarding Article, "Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease".
Topics: Clopidogrel; Humans; Lower Extremity; Peripheral Arterial Disease; Ticagrelor; Ticlopidine | 2017 |
Duration of Double Antiplatelet Therapy in Patients With Coronary and Peripheral Arterial Disease: The Key Might Be in the Type of Drug.
Topics: Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2017 |
Reply: Duration of the Double Antiplatelet Therapy in Patients With Coronary and Peripheral Arterial Disease: The Key Might Be in the Type of Drug.
Topics: Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Ticlopidine | 2017 |
Time trends in peripheral artery disease incidence, prevalence and secondary preventive therapy: a cohort study in The Health Improvement Network in the UK.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Clopidogrel; Female; Forecasting; | 2018 |
Letter by Henni et al Regarding Article, "Aspirin Monotherapy Should Not Be Recommended for Cardioprotection in Patients With Symptomatic Peripheral Artery Disease".
Topics: Aspirin; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Ticlopidine | 2018 |
Peripheral artery disease: How do genes and pharmacology interplay?
Topics: Aspirin; Clopidogrel; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Ticlopid | 2018 |
Regarding "A systematic review of the efficacy of aspirin monotherapy versus other antiplatelet therapy regimens in peripheral arterial disease".
Topics: Aspirin; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Ticlopidine | 2018 |
Clopidogrel responsiveness in patients undergoing peripheral angioplasty.
Topics: Aged; Angioplasty; Clopidogrel; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Limb Salva | 2013 |
Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Cohort Studies; Female; Humans; Longitudinal Studies; Male; | 2013 |
Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Pressure; Case-Control Studies; Clopidogrel; Endo | 2013 |
Residual thrombin generation potential is inversely linked to the occurrence of atherothrombotic events in patients with peripheral arterial disease.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Blood Platelets; Cardiovascular Diseases; Clopidogrel | 2014 |
Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty.
Topics: Adenosine Diphosphate; Aged; Angioplasty; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; | 2014 |
[Comparative assessment of antiaggregant efficacy of acetylsalicylic acid and clopidogrel in peripheral atherosclerosis].
Topics: Aged; Aspirin; Clopidogrel; Female; Humans; Lower Extremity; Male; Middle Aged; Patient Selection; P | 2014 |
SUPERA interwoven nitinol Stent Outcomes in Above-Knee IntErventions (SAKE) study.
Topics: Aged; Aged, 80 and over; Alloys; Ankle Brachial Index; Aspirin; Clopidogrel; Constriction, Pathologi | 2014 |
Adverse cardiovascular outcomes in relation to suboptimal antithrombotic therapy use in patients undergoing peripheral artery disease angioplasty: lost opportunities?
Topics: Aged; Aged, 80 and over; Angioplasty; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Female; | 2015 |
Response to dual antiplatelet therapy in patients with peripheral artery occlusive disease suffering from critical limb ischemia.
Topics: Aged; Aged, 80 and over; Area Under Curve; Aspirin; Clopidogrel; Critical Illness; Drug Resistance; | 2014 |
Complications of transbrachial arterial access for peripheral endovascular interventions.
Topics: Adult; Aged; Aged, 80 and over; Brachial Artery; Catheterization, Peripheral; Clopidogrel; Drug-Elut | 2015 |
Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease.
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; California; Cardiovascular Diseases; | 2015 |
Clopidogrel versus aspirin in patients with recent ischemic stroke and established peripheral artery disease: an economic evaluation in a Chinese setting.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cost-Benefit Analysis; Humans; Middle Aged; Pe | 2015 |
Resource use and costs in high-risk symptomatic peripheral artery disease patients with diabetes and prior acute coronary syndrome: a retrospective analysis.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors | 2016 |
High on-treatment platelet reactivity and outcomes after percutaneous endovascular procedures in patients with peripheral artery disease.
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Drug Resistance; Drug Therapy, | 2016 |
High On-Treatment Platelet Reactivity in Peripheral Arterial Disease: A Pilot Study to Find the Optimal Test and Cut Off Values.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Periph | 2016 |
Vascular disease: Ticagrelor not superior to clopidogrel for PAD.
Topics: Clopidogrel; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Ticagrelor; Ticlo | 2017 |
Editor's Choice - Dual Antiplatelet Therapy Improves Outcome in Diabetic Patients Undergoing Endovascular Femoropopliteal Stenting for Critical Limb Ischaemia.
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Clopidogrel; Constriction, Pathologic | 2017 |
Perioperative clopidogrel is associated with increased bleeding and blood transfusion at the time of lower extremity bypass.
Topics: Aged; Blood Loss, Surgical; Blood Transfusion; Chi-Square Distribution; Clopidogrel; Databases, Fact | 2017 |
State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.
Topics: Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Lactones; Male; Middle Aged; Myocardial Infarction | 2017 |
Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2017 |
Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de Riesgo y ENfermedad Arterial (FRENA) registry.
Topics: Aged; Cerebrovascular Disorders; Clopidogrel; Contraindications; Coronary Artery Disease; Drug Inter | 2011 |
Clopidogrel is not associated with major bleeding complications during peripheral arterial surgery.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Aspirin; Blood Transfusion; Chi-Square Distrib | 2011 |
Regarding "results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial".
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Drug Therapy, Combination; Graft Occlusi | 2011 |
Recent trends in Australian percutaneous coronary intervention practice: insights from the Melbourne Interventional Group registry.
Topics: Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Australia; Clopidogrel; Comorb | 2011 |
Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease.
Topics: Aged; Angioplasty; Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Female; Humans; Male; Mid | 2013 |
Clinical significance of the clopidogrel-proton pump inhibitor interaction after peripheral endovascular intervention for claudication.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Chi-Square Distribution; Clopidogrel; Comorbidity; Co | 2012 |
Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry).
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Atherectomy; Atorvastatin; Cardiovasc | 2013 |
Dual antiplatelet therapy in peripheral arterial disease and after peripheral percutaneous revascularization.
Topics: Aspirin; Clopidogrel; Endovascular Procedures; Hemorrhage; Humans; Peripheral Arterial Disease; Plat | 2012 |